Clinical trials
Patient clinical trials
Below are recruiting patient clinical trials, each written for real people, not researchers. We’re tracking 14,164 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04707300RecruitingPhase 1/Phase 2
HTLP injection to speed immune recovery after cord blood transplant
This Phase 1/2 study tests whether a specific immune-cell “starter” injection (HTLP) can help adults rebuild their immune system faster after an umbilical cord blood transplant for blood cancers. It mainly focuses on safety and whether immune recovery improves.
ParisAges 18–66 - NCT04768322Recruiting
LVAD versus standard heart failure medicines in advanced patients
This trial compares an LVAD device (a pump placed in the chest) plus medicines versus medicines alone for people with advanced, end-stage heart failure. It aims to see which approach works better to help patients live and stay out of the hospital.
BesançonAges 18 years+ - NCT04767568Recruiting
Testing a blood test to guide colorectal cancer screening care
This study looks at whether a simple blood test can help guide the care of people being evaluated for colorectal cancer. It may support earlier or clearer decision-making alongside existing screening or colonoscopy results.
BesançonAges 18 years+ - NCT04693663Enrolling by invitation
Relex-SMILE treatment for leftover nearsightedness after cataract surgery
This trial tests whether Relex-SMILE eye laser surgery can improve nearsightedness that remains after you’ve already had cataract surgery. It’s meant for people with a certain range of leftover nearsightedness, while excluding certain eye problems and prior eye procedures.
PristinaAges 20–70 - NCT04735172Recruiting
Brain scan to compare Parkinson chemical signals in early patients
This study uses a special 7‑Tesla MRI brain scan to measure tiny chemical (metabolite) differences in specific deep brain areas. It compares newly diagnosed, early-stage Parkinson’s patients who are not on Parkinson medication with healthy volunteers.
Clermont-FerrandAges 18–75 - NCT04739072Recruiting
Check colorectal cancer blood tests after curative treatment
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
Gilbert, ArizonaAges 18 years+ - NCT03829254RecruitingPhase 1/Phase 2
NUC-7738 treatment for advanced solid cancers and lymphoma
This early-phase study tests how safe NUC-7738 is and how it works in people with advanced solid tumors and certain lymphomas. Some participants may also receive pembrolizumab for specific cancers, aiming to improve cancer control while carefully monitoring side effects.
CambridgeAges 18 years+ - NCT04746625Recruiting
Test of an adjustable valve system for hydrocephalus shunts
This trial checks how safe and well a specific adjustable valve (Polaris 24) works in people with hydrocephalus who need a valve shunt. You may be eligible if you already have this valve implanted for a first shunt, a shunt replacement, or after an endoscopic procedure failed, and you do not have certain infection, bleeding, or heart-circulation conditions.
MarseilleAges Any age - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Birmingham, AlabamaAges 18 years+ - NCT04689152RecruitingPhase 3
Cell treatment via liver artery catheter for alcoholic cirrhosis
This Phase 3 trial tests whether a cell medicine called Cellgram-LC, delivered through a catheter into the liver artery, is safer and works better for people with alcoholic cirrhosis. It may help improve outcomes in people with more advanced liver scarring.
AnsanAges 20–71 - NCT04716452RecruitingPhase 1
Testing a ceramide liposome drug for relapsed or resistant AML
This Phase 1 trial tests a new targeted treatment (C6 ceramide in a tiny fat-like capsule) for adults with acute myeloid leukemia (AML) that has come back or did not respond to treatment. The goal is to see how the drug works and how safe it is in this setting.
Charlottesville, VirginiaAges 18 years+ - NCT04625049Enrolling by invitation
PET and MRI study in people with multiple sclerosis
This trial studies how certain brain immune activity relates to multiple sclerosis (MS) lesion growth and progression using PET and MRI scans. Your participation may help researchers understand disease changes over time and improve how MS is tracked.
Turku, Southwest FinlandAges 30–80 - NCT04653012Recruiting
Testing brain-activity recordings in people with drug-resistant epilepsy
This study looks at brain activity using electrodes placed inside the brain in people with focal, drug-resistant epilepsy before surgery. It may help doctors better map where seizures start and improve planning for treatment.
ParisAges 18 years+ - NCT04663399Recruiting
Study immune changes after stroke treatment
This study looks at how the body’s immune system responds after an acute ischemic stroke that may be treated with a procedure called mechanical thrombectomy. It may help doctors understand what immune changes happen after treatment and improve future care.
Paris, ParisAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Kingman, ArizonaAges 18 years+ - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Gilbert, ArizonaAges 18–70 - NCT04669171RecruitingPhase 1/Phase 2
Vaccine treatment for slow-growing lymphoma, alone or combined
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT04608110RecruitingPhase 1
Novel therapy for myelodysplastic syndrome
This study tests a new combination treatment for people with myelodysplastic syndrome (MDS), a blood disorder. The drug aims to slow the disease and improve blood counts, and might be an option for patients who haven't responded to other treatments.
Bunkyō CityAges 20 years+ - NCT04657822RecruitingPhase 4
Crizanlizumab rollover study for people with sickle cell disease
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
Birmingham, AlabamaAges 6 months–100 years - NCT04665206RecruitingPhase 1/Phase 2
Testing VT3989 for certain advanced cancers
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
San Francisco, CaliforniaAges 18 years+ - NCT04671771Recruiting
Testing a new graft for hemodialysis access in kidney failure
This study tests whether an “AV graft” implant works safely and well for people with end-stage kidney disease who need hemodialysis. It may help your dialysis access last and work better, compared with current expectations for AV grafts.
Phoenix, ArizonaAges 18–90 - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04604782RecruitingPhase 1/Phase 2
Regadenoson study in children to test safety and dosing
This trial tests how safe regadenoson is in children and how the body handles it after dosing. It also uses a heart “stress test” with MRI (CMR) when doctors feel it’s needed.
ParisAges 4 weeks–18 years - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+
Hear when a new Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient?
- Yes. Clin2 currently lists 14,164 recruiting patient studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.